Loading…
Ovarian vein sampling, and serum and urine testosterone monitoring in ovarian Leydig cell tumors: A report of two cases
Ovarian Leydig cell tumors are rare, testosterone-producing tumors that pose diagnostic challenges. A 36-year-old woman presented with 10 years of amenorrhea, facial hair growth and clitoromegaly. A 59-year-old woman presented after 2 years of voice deepening and terminal hair growth. Testosterone c...
Saved in:
Published in: | Case reports in women's health 2020-01, Vol.25, p.e00159-e00159, Article e00159 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Ovarian Leydig cell tumors are rare, testosterone-producing tumors that pose diagnostic challenges.
A 36-year-old woman presented with 10 years of amenorrhea, facial hair growth and clitoromegaly. A 59-year-old woman presented after 2 years of voice deepening and terminal hair growth. Testosterone concentrations were elevated for both patients; however, imaging failed to identify ovarian or adrenal pathology. For the first patient, selective ovarian venous sampling was performed with results suggesting right ovarian testosterone production. Right ovarian Leydig cell tumors were found in both patients after salpingo-oophorectomy. Testosterone levels immediately declined following tumor removal.
Additional diagnostic modalities, such as ovarian venous sampling, should be considered when the etiology of hyperandrogenism cannot be identified through lab work or imaging. In addition, sequential post-operative testosterone levels in serum or urine can help confirm adequate removal of the ovarian tumor.
•Pure Leydig cell tumors of the ovary are rare tumors diagnosed in two women with hyperandrogenism.•Ovarian vein sampling identified a right ovarian testosterone-producing tumor not seen on imaging.•Testosterone levels decreased 53% in one patient and 80% in the other within 3 hours of Leydig cell tumor removal. |
---|---|
ISSN: | 2214-9112 2214-9112 |
DOI: | 10.1016/j.crwh.2019.e00159 |